PD-L1 expression assessed by immunohistochemistry (IHC) was the first Food and Drug Administration (FDA)-approved companion or complementary diagnostic test for ICI monotherapy in NSCLC patients (24, 25). The gene discussed is CD274; the disease is non-small cell lung carcinoma.